Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events

Liver Transplantation

Volumn 20, Issue 7, 2014, Pages 791-797

  Watt, Kymberly D ^a   Fan, Chun ^a   Therneau, Terry ^a   Heimbach, Julie K ^a   Seaberg, Eric C ^b   Charlton, Michael R ^a  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INSULIN; LEPTIN; ORAL ANTIDIABETIC AGENT; RESISTIN; TACROLIMUS; APOLIPOPROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; END STAGE LIVER DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; GRAFT RECIPIENT; HEART ARREST; HEART FAILURE; HEART INFARCTION; HUMAN; HUMAN TISSUE; HYPERTENSION; INSULIN TREATMENT; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BLOOD; COMPLICATION; FEMALE; INFLAMMATION; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME;

ADIPOKINES; ADIPONECTIN; ADULT; AGED; APOLIPOPROTEIN B-100; APOLIPOPROTEINS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; END STAGE LIVER DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; LEPTIN; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RESISTIN; RISK FACTORS; TIME FACTORS;

EID: 84903158574     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23880     Document Type: Article

References (28)

1. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J,. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901-906.
2. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR,. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427.
3. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109-1114.
4. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
5. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S,. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 2005; 288: H2031-H2041.
6. Tiftikci A, Atug O, Yilmaz Y, Eren F, Ozdemir FT, Yapali S, et al. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. Arch Med Res 2009; 40: 294-298.
7. Anty R, Lemoine M,. Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol 2011; 35 (suppl 1): S10-S20.
8. Larsson H, Ahrén B,. Short-term dexamethasone treatment increases plasma leptin independently of changes in insulin sensitivity in healthy women. J Clin Endocrinol Metab 1996; 81: 4428-4432.
9. Nishimura K, Kishikawa H, Kato T, Kobayashi Y, Fujii N, Takahara S, Ichikawa Y,. Tacrolimus and angiotensin receptor blockers associated with changes in serum adiponectin level in new-onset diabetes after renal transplantation: single-center cross-sectional analysis. Transpl Int 2009; 22: 694-701.
10. Subramanian S, Trence DL,. Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am 2007; 36: 891-905.
11. Watt KD,. Metabolic syndrome: is immunosuppression to blame? Liver Transpl 2011; 17 (suppl 3): S38-S42.
12. Armstrong VW, Schütz E, Kaltefleiter M, Luy M, Helmhold M, Wieland E, et al. Relationship of apolipoproteins AI, B and lipoprotein Lp(a) to hepatic function of liver recipients during the early post-transplant period. Eur J Clin Invest 1995; 25: 485-493.
13. Tietge UJ, Böker KH, Manns MP, Bahr MJ,. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: E82-E89.
14. Hui CK, Zhang HY, Lee NP, Chan W, Yueng YH, Leung KW, et al.; for Hong Kong Liver Fibrosis Study Group. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J Hepatol 2007; 47: 191-202.
15. Chudek J, Adamczak M, Karkoszka H, Budziński G, Ignacy W, Funahashi T, et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003; 35: 2186-2189.
16. Pischon T, Hotamisligil GS, Rimm EB,. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003; 49: 650-652.
17. Varagunam M, Finney H, Trevitt R, Sharples E, McCloskey DJ, Sinnott PJ, et al. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis 2004; 43: 502-507.
18. Biadi O, Potena L, Fearon WF, Luikart HI, Yeung A, Ferrara R, et al. Interplay between systemic inflammation and markers of insulin resistance in cardiovascular prognosis after heart transplantation. J Heart Lung Transplant 2007; 26: 324-330.
19. Coss E, Watt KD, Pedersen R, Dierkhising R, Heimbach JK, Charlton MR,. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl 2011; 17: 23-31.
20. Kagan A, Haran N, Leschinsky L, Sarafian R, Aravot D, Dolberg J, et al. Serum concentrations of leptin in heart, liver and kidney transplant recipients. Isr Med Assoc J 2002; 4: 213-217.
21. Patel SB, Reams GP, Spear RM, Freeman RH, Villarreal D,. Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep 2008; 10: 131-137.
22. Momiyama Y, Ohmori R, Uto-Kondo H, Tanaka N, Kato R, Taniguchi H, et al. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2011; 18: 108-114.
23. Bahr MJ, Ockenga J, Böker KH, Manns MP, Tietge UJ,. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. Am J Physiol Endocrinol Metab 2006; 291: E199-E206.
24. Yagmur E, Trautwein C, Gressner AM, Tacke F,. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006; 101: 1244-1252.
25. Avramoglu RK, Basciano H, Adeli K,. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 2006; 368: 1-19.
26. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB,. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 3375-3383.
27. Spõsito AC, Vinagre CG, Pandullo FL, Mies S, Raia S, Ramires JA,. Apolipoprotein and lipid abnormalities in chronic liver failure. Braz J Med Biol Res 1997; 30: 1287-1290.
28. Walldius G, Jungner I,. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255: 188-205.